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Past studies have shown that partial ligation of the ductus arteriosus (DA) in late gestation fetal sheep provides a useful animal model for studying the pathogenesis and treatment of PPHN (4) . In this model, partial DA ligation increases pulmonary artery pressure without causing sustained elevations of pulmonary blood flow or hypoxemia, and PVR remains elevated at birth (4) . Along with changes in vascular tone, DA ligation causes vascular remodeling and severe PPHN with decreased responsiveness to iNO therapy (4, 36, 51) . How hemodynamic stress induced by hypertension disrupts normal PASMC signaling and function increasing proliferation and producing vascular remodeling in PPHN is unknown.
Rho kinase (ROCK) signaling is a complex pathway responsible for cellular proliferation, migration, differentiation and gene expression in diverse vascular beds (9) . ROCK activity has been shown to regulate smooth muscle cell (SMC) contraction and vascular tone in systemic and pulmonary circulations (6, 8) . In adult animal models of pulmonary hypertension, enhanced ROCK activity increases vascular tone, mediates calcium sensitization, and contributes to hypertensive remodeling (2, 9, 41, 50) . During lung development, ROCK activity maintains high pulmonary vascular tone and contributes to the myogenic response in the fetal lung (42, 48) . We have reported that increased ROCK activity alters pulmonary artery endothelial cell (PAEC) growth and impairs angiogenesis in experimental PPHN (19) . Whether high ROCK activity increases PASMC proliferation and contributes to vascular remodeling in PPHN is unknown.
Peroxisome proliferator-activated receptor (PPAR) is an early phylogenic member of the nuclear receptor superfamily, consisting of three isotypes: PPAR␣, PPAR␦, and PPAR␥ (1, 12, 15, 29) . PPAR␥ is abundantly expressed in vascular smooth muscle and endothelial cells in the normal lung (1, 52) and regulates SMC proliferation (52) . Selective PPAR␥ deletion in SMCs causes pulmonary hypertension and increased muscularization of distal vessels (22) , and activation of PPAR␥ decreases proliferation of PASMC in vitro (16, 22) . In adult models of pulmonary hypertension, PPAR␥ agonists prevent the development of vascular remodeling and pulmonary hy-pertension (PH) (10, 11, 21, 40) . This effect may be developmentally regulated as conflicting reports have been published in the neonate where PPAR␥ agonists improved air space growth, but had no effect on hypoxia-induced pulmonary vascular remodeling (39) . Decreased PPAR␥ signaling contributes significantly to PASMC proliferation in adult models of PH, but whether alterations in PPAR␥ signaling contribute to increased PASMC proliferation and vascular remodeling in PPHN is unclear.
Previous reports have demonstrated that PPAR␥ agonists produce vasodilation through inhibition of ROCK (5a, 26, 49) , but whether PPAR␥-ROCK interactions regulate SMC proliferation in PPHN remains unknown. Therefore, we hypothesized that increased PASMC ROCK expression and activity decreases PPAR␥ signaling, which increases SMC proliferation and contributes to vascular remodeling in PPHN. In this study we report increased proliferation, increased ROCK activity, and decreased PPAR␥ signaling in PPHN PASMCs and demonstrate that ROCK-PPAR␥ interactions contribute to vascular remodeling in experimental PPHN.
METHODS
Isolation and culture of fetal ovine PAECs. All procedures and protocols were reviewed and approved by the Animal Care and Use Committee at the University of Colorado Health Sciences Center, Aurora, CO. Fetal sheep from mixed-breed Columbia-Rambouillet pregnant ewes were used for all studies. Left and right pulmonary arteries were isolated at 135-140 days gestation (term ϭ 147 days), from late-gestation normal fetal sheep (n ϭ 4), and from fetal sheep that had undergone partial ligation of the DA in utero at 125-130 days gestation, 7-10 days prior to euthanasia (PPHN) (n ϭ 4) as previously described (18) .
SMC culture methods. Primary cultures of fetal PASMCs were prepared from conduit arteries isolated from late-gestation fetal lambs (135-140 days gestation; term ϭ 147 days). The adventitia was gently removed under sterile conditions and the vessel was washed in sterile phosphate-buffered saline (PBS). The vessel was sliced longitudinally and placed with the intima side down in a petri dish containing 0.5% collagenase (Worthington, Lakewood, NJ; catalog no. LS004174) for 10 min at 37°C. The intimal surface was then gently removed with a cell scraper. The remaining portion of the vessel was cut into small (1-2 mm) pieces and washed with HBSS (Fisher Scientific, Pittsburgh, PA; catalog no. 50-983-203), sodium bicarbonate (NaHCO 3) (20 mM), and HEPES (Fisher Scientific, catalog no. BP299-1) (10 mM) for 30 min in the 37°C hybridization oven. Fragments were placed in a SMC digest that consisted of 7.5 ml HBSS with 40 M Ca 2ϩ , 4.0 mg elastase (Roche, catalog no. 100907), 4.07 mg type 2 collagenase (Worthington, catalog no. LS04174 CLS-2), 15 mg albumin (Sigma, St. Louis, MO; catalog no. A9647), and 147 l soybean trypsin inhibitor (10 mg/ml) (Worthington, catalog no. LSO 3570) for 2 h in a 37°C hybridization oven. The digest was filtered through a 100-m cell strainer, washed with 5 ml of 10% FBS (Sigma, catalog no. F6178)/DMEM (Fisher Scientific catalog no. MT-15-018-CV) with 1% L-glutamine and 1% antibiotic-antimycotic and spun at 250 g for 6 min. The supernatant was removed and the pellet resuspended in 10% FBS/DMEM with 1% L-glutamine (Invitrogen, Grand Island, NY; catalog no. 25030081) and 1% antibiotic-antimycotic (Invitrogen, catalog no. 15240062) and transferred to the culture flask. Cells were maintained in culture containing 10% FBS, 1% antibioticantimycotic, and 1% L-glutamine, until they reached confluence. PASMC identity was confirmed by morphology and immunostaining with antibodies against ␣-smooth muscle actin, calponin, caldesmon, and desmin. All PASMC isolates demonstrate greater than 95% positive staining for the above SMC markers, indicating an absence of contamination with fibroblasts or endothelial cells. PASMC from four normal and PPHN animals were utilized for all experiments, with experiments performed at passage 3-6. Utilizing passage 3-6 cells allows for expansion and freezing of clones and subsequent use for multiple experiments.
siRNA transfection. PPAR␥ siRNA (Ovine) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA; catalog no. SC-156097) and siRNA transfection was performed per manufacturers' recommendations and protocol. PPAR␥ siRNA is an ovine-specific pool of three target-specific 19 -25 nt siRNAs designed to knock down PPAR␥ gene expression. Briefly, in a six-well tissue culture plate, 5 ϫ 10 5 cells per well were plated in 2 ml antibiotic-free normal growth medium supplemented with 10% FBS, at 37°C in 5% CO 2 incubator and allowed to adhere overnight. Growth medium was removed and transfection reagents (siRNA and Scramble) were added to duplicate wells for a final volume of 1 ml. Duplicate wells were utilized, allowing for molecular analysis of transfection efficacy and utilization of transfected cells for experiments outlined below. PPAR␥ siRNA (4 M) and control siRNA (Santa Cruz Biotechnology, catalog no. SC-37007) were mixed with equal parts of transfection reagent (Santa Cruz Biotechnology, catalog no. SC-29528) and added to the appropriate wells for 6 h. Multiple doses of siRNA (0 -8 M) were tested in preliminary experiments and 4 M was siRNA utilized because this dose produced the greatest knockdown of PPAR␥ expression and activity without causing apoptosis. Two control wells were also prepared receiving only antibiotic-free normal growth medium supplemented with FBS. After the 6-h incubation, normal growth medium with 20% FBS was added to each well without removal of the transfection mixture. Cells were incubated for an additional 18 -24 h and subsequently passaged for study. After passage, there was no further exposure to siRNA, and transfected cells were handled, utilizing the same conditions as controls. Western blot analysis was performed after passage on whole cell lysates and revealed a 37% decrease in total PPAR␥ protein expression and 32% decrease in the ratio of phosphorylated to total PPAR␥ protein (PPAR␥ activity) after siRNA treatment.
Cell growth. Fetal PASMCs from normal (n ϭ 4) and PPHN lambs (n ϭ 4) at passage 4 were plated at 2 ϫ 10 5 cells/well in a six-well plate and allowed to adhere overnight. Duplicate wells were plated for PASMC derived from each animal, and PASMCs were grown in DMEM supplemented with 10% FBS to initially determine whether under standard cell culture conditions differences exist between normal and PPHN PASMC proliferation. Daily cell counts were performed on duplicate wells for 5 days with a hemocytometer and experiments were repeated twice by the same methods to ensure reproducibility. The effect of PPAR␥ agonists rosiglitazone (Rosi 50 M) (Cayman Chemical, Ann Arbor, MI; catalog no. 71740) and 15-deoxy-delta 12,14 -prostaglandin J2 (15d-PG-J2; 10 M) (Cayman Chemical, catalog no. 18570), PPAR␥ siRNA (4 M) and ROCK inhibition (y-27632 5 M) (Cayman Chemical, catalog no. 129830-38-2) on cell growth were compared between PASMC from normal and PPHN fetal sheep. To determine the optimal dose for each agent, Western blot analysis was performed on normal and PPHN PASMC lysates for PPAR␥ protein expression and activity (total and phosphorylated PPAR␥) (Rosi, 15d-PG-J2, and PPAR␥ siRNA) and ROCK protein expression and activity (total and phosphorylated MYPT-1) (y-27632). We utilized the lowest dose of each agent for which the desired effect was seen. Growth studies were performed in DMEM supplemented with 5% serum, because this was the lowest serum concentration that supported fetal PASMC survival and proliferation. Medium was changed daily to ensure that degradation of drugs did not occur in culture.
MTT assay. The MTT assay measures cell proliferation of metabolically active cells by their mitochondrial activity. The tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT, a yellow chemical) is taken up by live cells and reduced or converted by mitochondrial reductase into a water insoluble purple formazan dye crystals. The amount of conversion can be measured with an ELISA reader. Briefly, MTT (Sigma, catalog no. M2128) was dissolved at 5 mg/ml in 1 ϫ PBS, and 10,000 PASMC from normal and PPHN fetal sheep were seeded per well of 96-well plates. MTT stock was added to each well at 1:10 dilution and incubated at 37°C for 6 h. The 96-well plates were spun at 220 g for 5 min, after which the supernatant was discarded and 150 l of 100% acidic isopropanol was added to each well. Optical density was determined with a microplate spectrophotometer at a wavelength of 570 nm.
Western blot analysis. PASMC from normal and PPHN fetal sheep were grown on 150 mm cloning dishes in DMEM supplemented with 5% serum. At confluence, cells were washed with ice cold PBS ϫ 2 and lysed in radioimmunoprecipitation (RIPA) buffer [PBS, 1% Nonidet P-40, 0.5%, sodium deoxycholate, 0.1% SDS, PMSF (10 mg/ml), aprotinin (16 l/ml), and sodium orthovanadate (1 mM)]. Cell lysates were scraped off the dishes, sonicated, and centrifuged at 10,000 g for 30 min at 4°C. The supernatant was removed and protein content in the supernatant was determined by the bicinchoninic acid assay [Pierce Biotechnology (catalog no. 23225) Rockford, IL], with bovine serum albumin as the standard. PASMC cell lysates were collected from four normal and PPHN animals and 20 g of protein sample per lane was resolved by SDS-polyacrylamide gel electrophoresis. Duplicate samples for each clone of cells or animal and condition were loaded; where samples from four normal and four PPHN animals could not be loaded on the same polyacrylamide gel, samples from one normal and one PPHN animal were loaded, allowing for comparison. Proteins from the gel were then transferred to nitrocellulose membrane.
PPAR␥/p-PPAR␥. After blocking, the blots were incubated overnight at 4°C with anti-PPAR gamma (catalog no. ab70405, Abcam, Cambridge, MA, 1:750 dilution), anti-p-PPAR␥ antibody (ab60953, Abcam; 1:750 dilution) diluted in 5% bovine serum albumin. Following overnight incubation blots were washed and subsequently incubated for 1 h at room temperature with goat anti-rabbit horseradish peroxidase (HRP)-conjugate secondary antibody (catalog no. SC2054, Santa Cruz Biotechnology 1:2,000). Bands of interest were visualized by enhanced chemiluminescence (ECL kit, Amersham Pharmacia Biotech, Buckinghamshire, UK or 2% ECL Advance Amersham Pharmacia Biotech) and identified by molecular weight as designated by the manufacturer for the protein of interest. PPAR-␥ activity is expressed as the ratio of phosphorylated (p)-PPAR␥/␤ actin to PPAR␥/␤ actin.
ROCKII. Blots were blocked for 30 min in 5% nonfat dry milk dissolved in buffer (10 mM Tris·HCl, 150 mM NaCl, 0.05% Tween-20, pH 8.0) Blots were incubated for 2 h at room temperature with anti-ROCK-II/ROCKϰ (BD610624 BD Biosciences, San Jose, CA) (1:500) diluted in 5% nonfat dry milk in buffer. After washing, blots were incubated for 1 h at room temperature with goat anti-mouse HRP-conjugated secondary antibody (Chemicon, Billerica, MA) (1: 10,000). Bands of interest were visualized by enhanced chemiluminescence (ECLϩ kit; Amersham Pharmacia Biotech, Buckinghamshire, UK), identified by molecular weight.
Phospho-MYPT-1/MYPT-1. Blots were blocked for 60 min with 5% nonfat dry milk dissolved in TBS with 0.5% Tween 20 (10 mM Tris·HCl, 150 mM NaCl, 0.5% Tween-20, pH 8.0). Blots were then incubated overnight with p-MYPT1 (Thr853) antibody (no. 4563 Cell Signaling, Danvers, MA) (1:1,000) and MYPT-1 (Cell Signaling) (1:1,000). After washing, blots were incubated for 1 h at room temperature with goat anti-rabbit HRP-conjugated secondary (Santa Cruz Biotechnology, SC2054). Bands of interest were visualized by enhanced chemiluminescence as previously described (18) . ROCK activity is expressed as the ratio of p-MYPT-1/␤ actin to MYPT-1/␤ actin.
All blots were stripped and reprobed with an antibody to ␤-actin (Sigma, A5316) as a loading control. Densitometry was performed using NIH Image (version 1.61) and changes in protein expression were analyzed after normalization for ␤-actin expression. For all figures representative blots are shown.
Study design. To assess ROCK-PPAR␥ interactions, at confluence, PASMCs were treated with angiotensin II (ANGII; 100 nM) and thromboxane A2 (TXA2; 1 M) to assess the effect of ROCK activation on PPAR␥ protein expression and activity. Y-27632 (5 M) treatment was used to assess the effect of ROCK inhibition on PPAR␥ protein expression and activity. PPAR␥ knockdown with specific siRNA was used to assess the effect of PPAR␥ inhibition on ROCK protein expression and activity. Western blots were performed for PPAR␥/p-PPAR␥; after 24 h of exposure to ROCK activators and inhibitors and for ROCKII, p-MYPT-1, and total MYPT-1 after treatment with PPAR␥ siRNA.
Statistical analysis. Data are presented as means Ϯ SE. Statistical analysis was performed with the Prism 4 software package (GraphPad Software, San Diego, CA). Statistical comparisons were made by analysis of variance for proliferation assays and Western blot analysis with Bonferroni posttest analysis. Unpaired t-test was used for MTT assay, proliferation assays, and Western blot analysis where appropriate. P Ͻ 0.05 was considered significant.
RESULTS

Increased proliferation of PASMC from PPHN fetal sheep.
Growth of normal and PPHN PASMC was assessed by performing daily cell counts for 5 days and MTT assay. Compared with controls, growth of PPHN PASMC increased by 44% on day 3 (P Ͻ 0.05), 49% on day 4 (P Ͻ 0.01), and 51% on day 5 (P Ͻ 0.01). By MTT assay, growth of PPHN PASMC increased by 29% (P Ͻ 0.05) (Fig. 1) . Despite significant differences in proliferation, normal and PPHN PASMC demonstrate identical cell morphology (Fig. 1) .
Increased ROCK protein expression and activity in PPHN PASMC. Western blot analysis on PASMC whole cell lysates from normal and PPHN fetal sheep demonstrates increased ROCK protein expression and activity. Compared with normal controls, ROCK protein expression (ROCKII) increased by 34% (P Ͻ 0.01) and activity (p-MYPT-1-to-MYPT-1 ratio) was 2ϫ greater (P Ͻ 0.01) in PPHN PASMC (Fig. 2) .
Decreased PPAR␥ protein expression and activity in PPHN PASMC. Western blot analysis on PASMC whole cell lysates from normal and PPHN fetal sheep demonstrate decreased PPAR␥ protein expression and activity in PPHN PASMC. Compared with controls, total PPAR␥ decreased by 27% (P Ͻ 0.05) and PPAR␥ activity (p-PPAR␥-to-PPAR␥ ratio) decreased by 32% (P Ͻ 0.01) in PPHN PASMC (Fig. 3) .
Effect of PPAR␥ activation and inhibition on PASMC proliferation. Growth of PPHN PASMCs was assessed in response to PPAR␥ agonists (Rosi 50 M and 15d-PG-J2, 10 M) (Fig. 4A) , and growth of normal PASMCs was assessed in response to PPAR␥ inhibition (PPAR␥ siRNA 4 M) (Fig. 4B ) by performing daily cell counts for 5 days. Both Rosi and 15d-PG-J2 decreased proliferation of PPHN PASMC, restoring growth to similar values seen in normal PASMC. Rosi and 15d-PG-J2 decreased proliferation by 42% (P Ͻ 0.05) and 46% (P Ͻ 0.05) on day 3, by 50% (P Ͻ 0.01) and 52% (P Ͻ 0.01) on day 4, and 51% (P Ͻ 0.01) and 55% (P Ͻ 0.01) on day 5 (Fig. 4A) . PPAR␥ siRNA increased proliferation of normal PASMC producing a hyperproliferative phenotype in normal PASMC as observed in PPHN PASMC. Normal PASMC growth increased by 31% (P Ͻ 0.05) on day 3, 44% on day 4 (P Ͻ 0.01), and 49% on day 5 (P Ͻ 0.01) (Fig. 4B) .
Effect of PPAR␥ activation and inhibition on ROCK protein expression and activity.
Effect of PPAR␥ activation on ROCK protein expression and activity was assessed by using PPAR␥ agonists (Rosi 50 M and 15d-PG-J2, 10 M) in normal and PPHN PASMC. Rosi decreased ROCK expression by 30% (Fig. 5A ) and activity (ratio of p-MYPT-1 to MYPT-1) by 51% (Fig. 5A ) and 15d-PG-J2 decreased ROCK expression by 30% (Fig. 5A ) and activity by 58% (Fig. 5A ) in normal PASMC. In PPHN PASMC, Rosi decreased ROCK expression by 41% (Fig. 5A ) and activity by 47% (Fig. 5A ) and 15d-PG-J2 decreased ROCK expression by 40% (Fig. 5A) , and activity by 53%. (Fig. 5A) . In normal fetal PASMC, PPAR␥ siRNA increased ROCK protein expression (ROCKII) by 46% (P Ͻ 0.01) and ROCK activity (p-MYPT-1-to-MYPT-1 ratio) by 50% (P Ͻ 0.01) (Fig. 5B) .
Effect of ROCK inhibition on PPAR␥ activity and proliferation in normal and PPHN PASMC. PPAR␥ activity was measured in whole cell lysates from normal and PPHN fetal PASMC in the presence and absence of ROCK inhibitor (y-27632, 5 M) (Fig. 6A) . At baseline, PPAR␥ activity (p-PPAR␥-to-PPAR␥ ratio) was decreased by 32% (P Ͻ 0.01) in PPHN PASMC and increased with y-27632 treatment. Y-27632 increased PPAR␥ activity by 54% in PPHN PASMC (Fig. 6A) , restoring PPAR␥ activity to normal values. ROCK inhibition had no effect on PPAR␥ activity in normal PASMC. Growth of normal and PPHN PASMC was assessed in the presence and absence of ROCK inhibitor (y-27632) (Fig. 6B) . ROCK inhibition decreased growth of PPHN PASMC by 37% on day 3 (P Ͻ 0.05), 47% on day 4 (P Ͻ 0.01) and 53% on day 5 P Ͻ 0.01 (Fig. 6B) . Y-27632 restored proliferation of PPHN PASMCs to similar values seen in normal untreated controls.
Growth of normal PASMC was unchanged in response to ROCK inhibition.
Effect of ROCK activation on PPAR␥ activity in normal and PPHN PASMC. The effect of ROCK activation (ANGII, 100 nM, and TXA2, 1 M) on PPAR␥ activity was measured by Western blot analysis on whole cell lysates from normal and PPHN fetal PASMC. ANGII and TXA2 decreased PPAR␥ activity (p-PPAR␥-to-PPAR␥ ratio) in normal PASMC by 35% (P Ͻ 0.01) and 33% (P Ͻ 0.01) and PPHN PASMC by 31% (P Ͻ 0.01) and 27% (P Ͻ 0.05), respectively (Fig. 7) .
DISCUSSION
Pulmonary hypertensive vascular remodeling with SMC hyperplasia contributes to impaired responsiveness to vasodilator therapy and poor outcomes in PPHN. We found that isolated PASMC from fetal sheep with experimental PPHN demonstrate a higher intrinsic growth rate than PASMC from normal fetal sheep and that this persistent hyperproliferative phenotype is partly due to enhanced ROCK activity. We also report that decreased PPAR␥ signaling increases ROCK activity, which enhances normal fetal PASMC proliferation. In addition, PPAR␥ activation decreases ROCK activity in PPHN PASMC and decreases cell growth to similar rates measured in controls. Overall, these findings suggest that PPAR␥-ROCK interactions contribute to high intrinsic rates of proliferation in PASMC from experimental PPHN.
Past studies have suggested multifactorial etiologies to the development of vascular remodeling in PPHN. Increased pulmonary blood flow in utero, hypoxia, or hyperoxia result in the release of various mediators including endothelin-1, platelet activating factor, reactive oxygen species, PDGF, transforming growth factor-␤ (TGF-␤), as well as increased RhoA/ROCK activity (17) . These mediators act to promote pulmonary vascular remodeling and SMC growth. Other mediators may inhibit vascular remodeling such as the NO/cGMP, VEGF, and PPAR␥ pathways (17) . Thus stimuli suppressing these inhibitory signaling mechanisms also contribute to pulmonary vascular remodeling (17) . The balance between stimulatory/ ROCK-mediated and inhibitory/PPAR␥-mediated pathways is essential for the prevention of vascular remodeling in PPHN; however, little is known about how these signaling pathways Prior studies of isolated PASMC in PH have addressed whether changes in PASMC proliferation contribute to the development of vascular remodeling. PASMC from adult patients with idiopathic and inherited PH have demonstrated increased proliferation under basal conditions in vitro (13, 16) and treatment with PPAR␥ agonist Rosi restored PASMC growth to normal (16) . Similarly, PASMC isolated from fawnhooded rats, which spontaneously develop PH with vascular remodeling after exposure to mild hypoxia, also demonstrate increased PASMC proliferation in vitro (25) . ROCK inhibition in this model prevents the development of vascular remodeling and PH (38) . ROCK and PPAR␥ are key regulators of PASMC proliferation (2, 9, 52) , and prior studies of ROCK and PPAR␥ in adult models of experimental PH have demonstrated that excessive ROCK activation and decreased PPAR␥ signaling contribute to the pathogenesis of vascular remodeling (2, 3, 10, 11, 21) . In these models, chronic ROCK inhibition and activation of PPAR␥ improved survival and prevented the development of vascular remodeling and PH (2, 3, 10, 11, 40) . These studies confirm the contribution of ROCK and PPAR␥ to the development of vascular remodeling in adult PH as well as their importance in the regulation of SMC proliferation.
To date there are no human studies evaluating whether changes in ROCK and PPAR␥ expression contribute to the development of neonatal PPHN. Although adult studies clearly implicate ROCK and PPAR␥ in the pathogenesis of PH, in neonates the contribution of these cell-signaling pathways to the development of PPHN is less clear. Bleomycin exposure in neonatal rat pups increases ROCK protein expression and activity, resulting in increased medial thickening and right ventricular hypertrophy (35) , and ROCK inhibition prevents the development of vascular remodeling and PH (30) . In our study we found increased ROCK protein expression and activity in PPHN PASMC, as well as rescue of the hyperproliferative PASMC phenotype in vitro with ROCK inhibition, confirming the importance of ROCK in regulating PASMC proliferation and its contribution to vascular remodeling in PPHN. Neonatal studies evaluating the efficacy of PPAR␥ agonists have focused on these agents in experimental rodent models of bronchopulmonary dysplasia (39, 44) , demonstrating improved alveolarization in these models (39, 44) , with less effect on preventing vascular remodeling (39) . In our study we found decreased PPAR␥ protein expression in PPHN PASMC and confirm the importance of PPAR␥ signaling in regulating PASMC growth. PPAR␥ silencing in normal PASMC increases PASMC proliferation, producing a phenotype similar to what is seen in PPHN PASMC. Treatment of PPHN PASMC with the PPAR␥ agonists Rosi and 15d-PG-J2 decreased proliferation of PPHN PASMC, restoring the PPHN PASMC growth characteristics to normal. These results confirm the importance of ROCK and PPAR␥ in the pathogenesis of pulmonary hypertension in neonates and provides the rationale and background for performing human studies.
Although our findings are consistent with studies of ROCK and PPAR␥ in adult PH, developmental differences exist with respect to the contribution of ROCK and PPAR␥ to the pathogenesis of PH. In adult models of pulmonary hypertension due to chronic hypoxia, inhibition of Rho-kinase activity prevents pulmonary hypertension and inhibits angiogenesis (23). Unlike these findings in the adult lung, experimental pulmonary hypertension in fetal sheep is associated with increased PAEC ROCK expression and impaired angiogenesis (19) . In this model, ROCK inhibition improves PAEC function and angiogenesis in vitro (19) . In addition, ROCK signaling plays an important role in lung branching morphogenesis during development and inhibition of ROCK during critical periods of development may potentiate lung hypoplasia (33) . With respect to PPAR␥ agonists, in rodent models of chronic hypoxia, similar developmental differences exist since Rosi prevented vascular remodeling in the adult but not the neonate (10, 11, 39) . To date, animal studies evaluating the safety and efficacy of ROCK inhibitors in vivo, in experimental bronchopulmonary dysplasia, have not demonstrated any adverse effects on neonatal lung development (30) . In contrast, the clinical use of PPAR␥ agonists has been limited by many of its adverse effects and toxicities (7) . The developmental differences that exist with respect to the contribution of ROCK and PPAR␥ to the pathogenesis of PH, as well as the potential toxicities of ROCK inhibitors and PPAR␥ agonists during critical stages of lung development, make it essential to understand the role ROCK and PPAR␥ play in the pathogenesis of PPHN in a developmentally relevant model. Our data extend these observations by demonstrating increased PASMC proliferation in the developing lung after prolonged exposure to hemodynamic stress and changes in ROCK and PPAR␥ signaling that contribute to this in vitro hyperproliferative phenotype. This is the first study in PPHN to demonstrate a change in PASMC phenotype that persists in vitro, after partial ligation of the DA in utero. ROCK activity and protein expression were increased and PPAR␥ protein expression and activity decreased in PPHN PASMC, and inhibition of ROCK and activation of PPAR␥ restored proliferation by PPHN PASMC to normal values, suggesting that increased ROCK or decreased PPAR␥ is responsible for the increased PPHN PASMC proliferation. However, the separate and interactive effects of these two pathways in the regulation of PASMC proliferation in PPHN have not been previously studied.
Both ROCK and PPAR␥ regulate SMC proliferation (2, 9, 50) and contribute to the pathogenesis of PH (2, 3, 10, 11, 21, 40) , but whether these pathways interact to produce vascular remodeling in PPHN is unknown. This is the first study of SMCs isolated from the pulmonary vasculature from an experimental model of PPHN, demonstrating that ROCK-PPAR␥ interactions contribute to increased PASMC proliferation and vascular remodeling in PPHN. ROCK activity and PASMC proliferation were significantly increased and PPAR␥ expression significantly decreased in PPHN PASMC and activation of ROCK with ANGII and TXA2 decreased PPAR␥ expression. ROCK inhibition decreased PPHN PASMC proliferation and increased PPAR␥ expression in PPHN but not normal PASMC, restoring proliferation by PPHN PASMC to normal values. Since ROCK and PPAR␥ are important regulators of PASMC proliferation, the possibility exists that the phase of the cell cycle is responsible for determining the expression of ROCK and PPAR␥ rather than a pathological process. However, our findings support the hypothesis that increased PASMC ROCK expression and activity are responsible for decreased PPAR␥ signaling and increased PPHN PASMC proliferation since the effect of ROCK inhibition on PASMC proliferation and PPAR␥ expression was specific to PPHN PASMC, decreasing the likelihood that ROCK and PPAR␥ expression was determined by the proliferative phase of the cell. Published reports have implicated ANGII as important regulator of PPAR␥ expression in vascular SMCs, through secretion of TGF-␤ 1 and via phosphorylation of p38 mitogenactivated protein kinase and histone deacetylase 3 (21, 46) . Our study and others confirm the importance of ANGII in the regulation of ROCK protein expression and activity (5a) and suggest that ANGII, through activation of ROCK and secretion of TGF-␤ 1 , is responsible for decreased PPAR␥ expression and the link between ROCK and PPAR␥ in PPHN PASMC.
Prior reports suggest that PPAR␥ may play an important role in the regulation of ROCK (5a, 49). In isolated aortic SMC, pioglitazone (PPAR␥ agonist) prevented activation of ROCK at baseline and in response to ROCK agonists (ANGII) (5a). Wakino et al. (49) expanded on this in vitro finding demonstrating the efficacy of pioglitazone, in decreasing ROCK activity in vivo, in spontaneously hypertensive rats (SHR). The SHR develop systemic hypertension that occurs in the setting of increased ROCK activity. The PPAR␥ agonist pioglitazone decreased ROCK activity and restored blood pressure to normal (49) . Contrasting this observation, Crossno et al. (11) demonstrated the efficacy of PPAR␥ agonists in preventing vascular remodeling and right ventricular hypertrophy after chronic hypoxia but still found equal elevations in mean pulmonary arterial pressure. Fasudil (ROCK inhibitor) acutely normalized pulmonary arterial pressure, suggesting that PPAR␥ agonists were ineffective in preventing ROCK-mediated vasoconstriction. Our studies confirm cross talk between PPAR␥ and ROCK as silencing of PPAR␥ with siRNA, increased ROCK activity, and activation of PPAR␥ decreased ROCK activity. These findings support prior observations and suggest a role for PPAR␥ agonists in regulating ROCK activity (5a, 49) . Because concerns exist with respect to the side effects of PPAR␥ agonists, inhibition of ROCK may be an effective strategy for modulating PPAR␥ activity, restoring PASMC proliferation to normal and preventing vascular remodeling in PPHN.
Potential limitations of this study include the use of fetal PASMC harvested from relatively large vessels and that differences may exist in the behavior of these cells compared with more distal PASMCs. Although more distal PASMC may better represent where vascular remodeling occurs during development, studying organ-specific cells from a developmentally relevant model of PPHN and the use of multiple clones of cells from different animals are strengths of our study. Another potential limitation is the fact that the efficacy of ROCK inhibitors and PPAR␥ agonists was only measured in vitro. Our in vitro studies provide mechanistic insights into the pathogenesis of vascular remodeling in severe PPHN and lay the foundation for future studies to address whether modulators of these pathways can prevent vascular remodeling in vivo in experimental PPHN. Because controversy exists as to the efficacy of PPAR␥ agonists in preventing vascular remodeling after exposure to chronic hypoxia in neonatal rats pups, future experiments exploring whether chronic inhibition of ROCK or activation of PPAR␥ can prevent vascular remodeling in experimental PPHN in vivo are crucial. To date there are no studies of PPAR␥ and ROCK in human neonatal tissue; this study provides the rationale for pursuing these important cellsignaling pathways in future studies of human tissues. The use of serum as well as passaged cells for the cell proliferation and molecular studies may potentially produce a hyperproliferative PASMC phenotype in vitro that differs significantly from the in vivo phenotype. This experimental model of PPHN is characterized by vascular remodeling in vivo, and this study provides insights into mechanisms responsible for vascular remodeling in this model. Although the use of serum is a limitation of the study, despite identical cell culture conditions, striking phenotypic differences exist between normal and PPHN PASMC with respect to cellular function and cell-signaling pathways. The possibility exists that the effect of PPAR␥ agonists on PASMC signaling and cellular function are secondary to offtarget effects, rather than enhancement of PPAR␥ signaling. At the doses utilized, preliminary studies demonstrated enhanced PPAR␥ activity with both Rosi and 15d-PG-J2. Furthermore we demonstrate similar effects on cell signaling and function with the use of the two agents Rosi and 15d-PG-J2, minimizing the possibility that the effect of these agents was secondary to off-target effects.
In conclusion, we found that PASMC from fetal sheep with PPHN have high intrinsic rates of proliferation and that high ROCK activity is partly responsible for this persistent hyperproliferative phenotype in vitro. In addition, we found that PPAR␥ activation decreases ROCK activity and PASMC proliferation and restores proliferation by PPHN PASMC to growth rates that are similar to normal fetal PASMC and that inhibition of PPAR␥ signaling in normal PASMC increases ROCK activity and enhances proliferation. Overall, these findings suggest that cross talk between ROCK and PPAR␥ signaling pathways play a key role in the regulation of fetal PASMC growth and contributes to high proliferation of PPHN PASMC. We speculate that therapies aimed at inhibition of ROCK or activation of PPAR␥ would be effective in preventing vascular remodeling and improving outcomes in severe PPHN.
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